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Background: Cardiac hypertrophy is characterized by alterations in both cardiac bioenergetics and insulin
sensitivity. Insulin promotes glucose uptake by cardiomyocytes and its use as a substrate for glycolysis and
mitochondrial oxidation in order to maintain the high cardiac energy demands. Insulin stimulates Ca2+ release from
the endoplasmic reticulum, however, how this translates to changes in mitochondrial metabolism in either healthy
or hypertrophic cardiomyocytes is not fully understood.
Results: In the present study we investigated insulin-dependent mitochondrial Ca2+ signaling in normal and
norepinephrine or insulin like growth factor–1-induced hypertrophic cardiomyocytes. Using mitochondrion-selective
Ca2+-fluorescent probes we showed that insulin increases mitochondrial Ca2+ levels. This signal was inhibited
by the pharmacological blockade of either the inositol 1,4,5-triphosphate receptor or the mitochondrial Ca2+
uniporter, as well as by siRNA-dependent mitochondrial Ca2+ uniporter knockdown. Norepinephrine-stimulated
cardiomyocytes showed a significant decrease in endoplasmic reticulum-mitochondrial contacts compared to either
control or insulin like growth factor–1-stimulated cells. This resulted in a reduction in mitochondrial Ca2+ uptake,
Akt activation, glucose uptake and oxygen consumption in response to insulin. Blocking mitochondrial Ca2+ uptake
was sufficient to mimic the effect of norepinephrine-induced cardiomyocyte hypertrophy on insulin signaling.
Conclusions: Mitochondrial Ca2+ uptake is a key event in insulin signaling and metabolism in cardiomyocytes.
Keywords: Insulin, Calcium, Mitochondria, Cardiac hypertrophy, Inositol 1,4,5-triphosphate receptor, Akt, IGF-1,
CatecholaminesBackground
Cardiac hypertrophy is a physiological process that occurs
in response to an increase in heart workload. Initially, it
can be compensatory, however, a chronic elevated work-
load, the neurohumoral input, or an underlying genetic
mutation can lead to pathological hypertrophy, contractile
dysfunction, ventricular dilatation, and finally, heart failure
[1]. Moreover, during pathological hypertrophy, the heart
undergoes significant changes in metabolism [2]. Cardiac* Correspondence: slavander@uchile.cl
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unless otherwise stated.metabolism is flexible, with fuel preferences switching
from primarily glycolysis in the foetal heart, to β-oxidation
of lipids in the adult heart [3]. During pathological hyper-
trophy, there is a re-activation of the so called “foetal gene
program” and an increased preference for glucose oxida-
tion [4,5].
The cellular signalling pathways involved in the hyper-
trophic response have been widely studied and Ca2+ is
known to play a key role [1]. Diverse proteins activated
by an elevation in cytosolic Ca2+ have been associated
with the development of cardiac hypertrophy, such as
the protein phosphatase calcineurin, Ca2+-calmodulin
kinase II and protein kinase C [6-8]. Mitochondria are
another important target of Ca2+ signalling. Mitochon-
drial Ca2+ uptake is essential for cell bioenergetics; thus
an equilibrated rise in mitochondrial Ca2+ concentrational Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and ATP synthesis [9,10]. Mitochondrial Ca2+ uptake is
carried out primarily by the mitochondrial Ca2+ unipor-
ter (MCU) [11]. This uniporter is a highly selective Ca2+
channel, but with low affinity [12]. Thereby, high
cytosolic-Ca2+ concentrations in the proximity of mito-
chondria must occur to induce Ca2+ entry. To solve this
problem, mitochondria are strategically localized to high
Ca2+ concentration microdomains near Ca2+ release
channels of the endoplasmic reticulum (ER) [13,14]. The
close contacts formed between ER and mitochondria are
regulated by a great variety of proteins located in the inter-
face of the two organelles, including the inositol 1,4,5-tri-
phosphate receptor (InsP3R), the ryanodine receptor
(RyR), the sarco/endoplasmic reticulum Ca2+-ATPase
(SERCA) and mitofusin-2 (Mfn2) [15,16].
Insulin is a key regulator of metabolism and plasma
glucose levels [17]. In the heart, insulin promotes glu-
cose uptake into cardiomyocytes and its use as an en-
ergy source by activating glycolysis and mitochondrial
oxidative phosphorylation [18]. Recently, we showed
that insulin increases cytoplasmic Ca2+ levels by a
mechanism that involves the sequenced activation of
phosphatidilinositol-3 kinase (PI3K) and phospholip-
ase C (PLC) to increase the mass of InsP3. This axis
induces Ca2+ release from the InsP3R, that can influ-
ence translocation of the facilitated glucose trans-
porter GLUT4 to cell surface and glucose uptake [19].
Mitochondrial Ca2+ uptake can also affect cytoplasmic
Ca2+ signals, by acting as a Ca2+ buffer after an in-
crease in cytoplasmic levels. Moreover, it has been
shown that, in addition to helping buffer large cytoplasmic
Ca2+ fluctuations, the maintenance of optimal mitochon-
drial function is dependent on continual, constitutive Ca2+
transfer from ER to mitochondria to support oxidative
phosphorylation [9]. During pathological cardiac hyper-
trophy, the heart develops insulin resistance, resulting in a
slower rate of glucose entry in response to insulin and a
decrease in the capacity for glucose oxidation [20,21],
without changes in the expression of GLUT4 transporters
[22].
The current study was designed to understand the mech-
anisms integrating mitochondrial Ca2+ uptake and insulin
signaling in normal and hypertrophic cardiomyocytes. We
show that insulin-induced stimulation of oxidative meta-
bolism occurs through mitochondrial uptake of the Ca2+
released from ER. This mechanism is diminished in nor-
epinephrine (NE)-treated cardiomyocytes undergoing
pathological hypertrophy, but not in insulin like growth
factor-1 (IGF-1)-treated hypertrophic cardiomyocytes.
Moreover, pharmacological inhibition of mitochondrial
Ca2+ uptake reduces insulin-dependent activation of the ca-
nonical Akt pathway. Thus, Ca2+ transfer to mitochondria
emerges as an important new regulator of insulin signaling.Results
Insulin induces an increase in mitochondrial Ca2+ uptake
Previous reports showed that insulin stimulation leads
to an increase in cytoplasmic Ca2+ levels by releasing
Ca2+ from the ER [19]. However, it is unknown whether
the Ca2+ signal triggered by insulin has a mitochondrial
component. To examine this, changes in mitochondrial
Ca2+ levels were measured in cardiomyocytes using the
mitochondrial-directed Ca2+ indicator Rhod-FF. This
probe had a Pearson coefficient of 0.92 with the mito-
chondrial probe MitoTracker Green in colocalization ana-
lysis, showing a high degree of mitochondrial destination
(Additional file 1: Figure S1A). Once loaded with Rhod-FF,
changes in mitochondrial Ca2+ levels were measured via
confocal microscopy. As a control, at the end of each meas-
urement, carbonyl cyanide m-chlorophenyl hydrazone
(CCCP) was added to dissipate mitochondrial membrane
potential (ΔΨm) releasing mitochondria-localized Ca2+ to
the cytoplasm (Additional file 1: Figure S1B). Because
Rhod-FF at high concentrations can alter mitochondrial
morphology [23] we also analyzed mitochondrial mean vol-
ume and number [24,25] in cells treated with MitoTracker
Green and Rhod-FF (Additional file 1: Figure S1C-D). No
significant differences were found in these parameters
suggesting that under our conditions, treatment with
Rod-FF did not impact mitochondrial morphology.
As shown in Figure 1A, mitochondrial Ca2+ levels in-
creased in cardiomyocytes after insulin stimulation.
Pharmacological inhibition was used to test the participa-
tion of various Ca2+ channels. It has been shown that
MCU is one of the primary Ca2+ channels involved in
mitochondrial Ca2+ uptake in cardiomyocytes [26]. To test
whether MCU participates in insulin-induced mitochon-
drial Ca2+ uptake, cardiomyocytes were pre-treated with
the MCU inhibitor Ruthenium Red (Ru) for 30 min prior
insulin stimulation. As shown in Figure 1B, there was a sig-
nificant reduction in mitochondrial Ca2+ uptake after insu-
lin stimulation in Ru-treated cardiomyocytes. Next,
participation of InsP3R was evaluated by pre-treating cardi-
omyocytes with an InsP3R–specific inhibitor xestospongin
C (XeC). XeC also reduced the insulin-induced mitochon-
drial Ca2+ signal (Figure 1C). To further confirm the par-
ticipation of InsP3R, PLC was blocked with U73122, thus
inhibiting InsP3R Ca
2+ release by preventing the synthesis
of its ligand. Figure 1D shows that cardiomyocytes pre-
treated with U73122 had a reduced mitochondrial Ca2+
signal after insulin stimulation. To evaluate whether RyR
hannels also contribute to this mitochondrial Ca2+ signal,
RyR channels were inhibited by preincubating cardiomyo-
cytes with ryanodine. Figure 1E shows that the insulin-
induced increase in mitochondrial Ca2+ was unaltered in
cardiomyocytes pre-treated with ryanodine. In conclusion,
Ru, XeC and U73122 pre-treatment caused a significant
reduction in the area under the curve of the insulin-
Figure 1 Insulin increases mitochondrial Ca2+ through an InsP3R dependent pathway. A) Confocal images of insulin-induced mitochondrial
Ca2+ signal captured at the indicated times in cardiomyocytes loaded with Rhod-FF 5,4 μM. B-E) Representative measures of fluorescence-associated
insulin-induced mitochondrial Ca2+ signals in cardiomyocytes pre-treated with (gray line) or without (Ctrl, black line) the respective inhibitors for 30 min.
Insulin (100 nM) was added at 100 s. B) Ruthenium Red (Ru), 10 μM; C) xestospongin C (XeC), 100 μM; D) U73122 (U73), 10 μM and E) Ryanodine (Rya),
50 μM. F) Area under the curve of insulin-induced mitochondrial Ca2+ signals of control, Ru, XeC, U73 and Rya pre-treated cardiomyocytes after insulin
stimulation between 100 and 300 s. The results are representative of 3 independent experiments (N= 3), where 10–20 cells were analysed. Data are
expressed as mean ± SEM, *P < 0.05 vs. Ctrl. G) Measurement of insulin-induced mitochondrial Ca2+ signal in cardiomyocytes transfected with a siRNA
control (black line) or a siRNA against MCU (gray line). Insulin (100 nM) was added at 100 s. H) Area under the curve of insulin-induced mitochondrial
Ca2+ signals of control and siRNA-mCU treated cardiomyocytes. The results are representative of 3 independent experiments (N = 3), where 10–20 cells
were analysed. Data are expressed as mean ± SEM, **P < 0.01 vs. siRNA Ctrl.
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not (Figure 1F).
High concentrations of Ru can bind non-specifically
to phospholipid membranes [27] potentially altering
intracellular Ca2+ concentrations in our experiments.
To control this, we used Fura2 to assess changes in cyto-
plasmic Ca2+ at baseline and after the addition of CCCP
(50 μM) or thapsigargin (Thapsi, 500 μM) to deplete
mitochondrial or ER Ca2+, respectively in cells treated
with and without Ru (10 μM) for 3 h (Additional file 2:
Figure S2A-C). No significant difference was found in
basal cytoplasmic Ca2+ levels of cells treated with Ru in
comparison with control cells, however, there was a slight,
but not significant, decrease in the rate of Ca2+ increase(slope, [(F340/F380)/Time)] evoked with both stimuli,
CCCP and Thapsi. Moreover, to further confirm the
involvement of MCU in our model we used a complemen-
tary approach to alter MCU activity that was independent
of any nonspecific effects of Ru. Cardiomyocytes were tran-
siently transfected with a small interfering RNA (siRNA)
against MCU, reaching a knockdown of 72%, 72 h post
transfection (Additional file 2: Figure S2D-E). There
was a significant reduction on insulin-induced mito-
chondrial Ca2+ uptake in siRNA-MCU depleted cells com-
pared to cardiomyocytes transfected with a control siRNA
(Figure 1G and H). Taken together, these results identify
the insulin-induced increase in mitochondrial Ca2+ as a
PLC/InsP3R/MCU dependent pathway.
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reduced in norepinephrine-treated hypertrophic
cardiomyocytes
During pathological hypertrophy, the heart develops sig-
nificant changes in energy metabolism, shifting to an insu-
lin resistant state [4]. To test whether the insulin-induced
mitochondrial Ca2+ signal described here is altered in
pathological hypertrophy, we evaluated this response in
cardiomyocytes pre-treated with the adrenergic agonist
NE (10 μM) for 24 h to induce hypertrophy (Additional
file 3: Figure S3). Insulin-dependent mitochondrial Ca2+
uptake was reduced in the NE-treated cardiomyocytes
compared to control cells (Figure 2A). Importantly, the
insulin-induced increase in cytoplasmic Ca2+ levels was
not reduced compared to controls in the NE-treated cardi-
omyocytes, as evaluated using Fluo3-AM (Figure 2B).
Next, IGF-1-induced hypertrophy was used as an in vitro
model of physiological hypertrophy [28]. Cardiomyocytes
were treated with IGF-1 for 24 h prior to insulin stimula-
tion. The mitochondrial Ca2+ signal induced by insulin
was not reduced in IGF-1-treated cardiomyocytes com-
pared to controls (Figure 2C and D), suggesting that the
changes in mitochondrial Ca2+ uptake may be unique to
the NE-induced pathological hypertrophy. To determine
whether the reduction in mitochondrial Ca2+ uptake ob-
served in NE-treated cardiomyocytes was due to a change
upstream or downstream of Ca2+ release from ER, hista-
mine was used to stimulate InsP3R-dependent Ca
2+ release
from the ER. Mitochondrial Ca2+ uptake after histamine
stimulation was also reduced in NE-treated hypertrophic
cardiomyocytes compared to control cells (Figure 2E
and F). These results suggest that insulin-dependent mito-
chondrial Ca2+ uptake is lower in NE-treated cardio-
myocytes (pathological hypertrophy) compared with control
conditions. Importantly, this inhibitory effect appears not to
be operative in IGF-1-treated cardiomyocytes (physiological
hypertrophy) and thus is not simply a requisite change in
response to cell growth. Moreover, histamine-dependent
mitochondrial Ca2+ uptake was decreased in NE-treated
cardiomyocytes, suggesting that changes in mitochondrial
Ca2+ uptake in NE-treated cardiomyocytes occur down-
stream of Ca2+ release from ER and are not due to an
upstream change in the insulin signaling. Interestingly,
Ca+2 release from the ER after Thapsi treatment is
augmented in NE-treated cardiomyocytes in comparison
to control and IGF-1-treated cardiomyocytes, further indi-
cating that the reduction in mitochondrial Ca2+ uptake is
not due to a reduction in ER Ca2+ loading (Additional file 4:
Figure S4).
ER-mitochondria coupling is reduced in NE-treated
hypertrophic cardiomyocytes
The distance between ER and mitochondria is a key de-
terminant of Ca2+ transfer between these organelles [29].To evaluate whether this parameter was altered in the
NE-treated cardiomyocytes, the colocalization of ER and
mitochondria was measured using organelle specific fluor-
escent probes and confocal microscopy. Figure 3A shows
representative images of control and NE or IGF-1 treated
cardiomyocytes labeled with ER-Tracker red and
MitoTracker green, to detect ER and mitochondria,
respectively. The colocalization of these organelles was
assessed in the whole cell by the quantification of
Manders’ coefficient [30,31] which is a relative measure of
the percentage of one structure in contact with other. The
Manders’ coefficient M1 denotes the fraction of ER that
colocalizes with mitochondria (Figure 3B), whereas the
Manders' coefficient M2 denotes the fraction of mitochon-
dria that colocalizes with ER (Figure 3C). M2 was signifi-
cantly reduced in NE-treated cardiomyocytes compared
with controls, indicating movement of mitochondria away
from sites of contact with the ER. M1 did not change. To-
gether with the Ca2+ uptake results, this data suggest there
is a decrease in both physical and functional ER-
mitochondrial coupling during pathologic hypertrophy.
IGF-1-treated cardiomyocytes showed no change in either
coefficient, consistent with maintenance of ER-
mitochondria coupling during IGF-1-induced physiological
hypertrophy. To further analyse the ER-mitochondria
interaction, we measured the Manders’ coefficient using an
algorithm for the ImageJ software previously developed by
our group that is designed to scan the cell radially from the
centre of the nucleus towards the plasma membrane in a
full angle (0-360°), as illustrated in the upper left hand box
of Figure 3A [31]. In this analysis, the control cells showed
little variation in either Manders’ coefficient across the
various regions of the cell, indicating that ER-mitochondria
coupling is homogeneously distributed throughout the cell.
Interestingly, this homogeneous distribution was main-
tained after either NE or IGF-1 treatment (Figure 3D
and E). The reduction in M2 observed in NE-treated cardi-
omyocytes was observed in perinuclear, central, and radial
regions, indicating that the reduction in ER-mitochondrial
coupling occurs throughout the cardiomyocyte (Figure 3E).
Because we previously identified InsP3R as the primary
Ca2+ channel involved in Ca2+ transfer to the mitochondria,
we evaluated the subcellular distribution of the most
expressed InsP3R type 2 isoform (InsP3R2) and the
mitochondrial marker mtHsp70. Figure 3F and G shows a
reduction in the colocalization of InsP3R2 and the mito-
chondrial marker mtHsp70 in NE-treated cardiomyocytes
compared to vehicle treated controls. In this case, both M1
and M2 were significantly reduced. We realize that there
are important differences between the ER-mitochondrial
interface in a functioning heart compared to cultured cells.
Therefore a comprehensive validation of the differences
between the two conditions is beyond the scope of our
































































































Figure 2 Reduction in insulin-dependent mitochondrial Ca2+ uptake in NE-induced hypertrophic cardiomyocytes. Representative
measures of fluorescence-associated insulin-induced Ca2+ signals in cardiomyocytes pre-treated with (gray line) or without (Ctrl, black line) the respective
hypertrophic inducers for 24 h. Insulin (100 nM) was added at 100 s. A) Mitochondrial Ca2+ signals in cardiomyocytes treated with NE 10 μM for 24 h.
B) Cytoplasmic Ca2+ signals in cardiomyocytes treated with NE 10 μM for 24 h. C) Mitochondrial Ca2+ signals in cardiomyocytes treated with IGF-1 100 nM
for 24 h. D) Area under the curve of mitochondrial Ca2+ signals of control and IGF-1 and NE treated cardiomyocytes after insulin stimulation between 100
and 300 s. The results are representative of 3 independent experiments (N = 3), where 10–20 cells were analysed. Data are expressed as mean ± SEM,
*P < 0.05 vs. Ctrl. E) Measurement of histamine-induced mitochondrial Ca2+ signal in cardiomyocytes treated with NE 10 μM for 24 h. Histamine (100 mM)
was added at 100 s. F) Area under the curve of mitochondrial Ca2+ signals of control and NE treated cardiomyocytes after histamine stimulation between
100 and 300 s. The results are representative of 3 independent experiments (N = 3), where 10–20 cells were analysed. Data are expressed as mean ± SEM,
*P < 0.05 vs. Ctrl.
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experimentation will be required to validate this.
Next, we tested if the reduction in ER-mitochondria
coupling in NE-treated cardiomyocytes correlated with achange in mitochondrial metabolism. The rate of oxygen
consumption was significantly reduced in NE-stimulated
cardiomyocytes compared to controls. (78 ± 4, p <0.05)
(Figure 3H). Oxygen consumption in IGF-1-stimulated
Figure 3 (See legend on next page.)
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Figure 3 ER-mitochondria coupling is reduced in NE-induced hypertrophic cardiomyocytes. A) Representative confocal images of
cardiomyocytes stained with MitoTracker green 200 nM for 30 min (Mitochondria, green) and ER-Tracker red 400 nM for 30 min (ER, red), treated with NE
10 μM or IGF-1 100 nM for 24 h. Scale bar: 10 μm. B-C) Quantification of the Manders’ coefficient M1 (fraction of ER in colocalization with mitochondria),
or M2 (fraction of mitochondria in colocalization with ER). Data are expressed as mean ± SEM, N = 3, *P < 0.05 vs. Ctrl. D-E) Quantification of the M1 and
M2 coefficients within the predefined subcellular regions [perinuclear (peri), central and radial]. Data are expressed as mean ± SEM, N = 3, *P < 0.05 vs.
Control. F) Representative confocal images of cardiomyocytes stained for InsP3R2 (green) and mtHsp70 (red), treated with NE 10 μM for 24 h. Scale bar:
20 μm. G) Quantification of the Manders’ coefficient M1 (InsP3R2 overlapping mtHsp70) and M2 (mtHsp70 overlapping InsP3R2). Data are expressed as
mean ± SEM, N = 3, **P < 0.01 vs. Ctrl. H) Oxygen consumption rate of cardiomyocytes treated with NE 10 μM or IGF-1 100 nM for 24 h. Data are
expressed as mean ± SEM, N = 6, *P < 0.05 and **P < 0.01 vs. Control (ctrl).
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comparison to control cells. All together, these data indi-
cate that NE-induced pathologic hypertrophy causes a
reduction in the physical association between ER and
mitochondria and a reduction in mitochondrial meta-
bolism, whereas IGF-1-induced physiologic hypertrophy
does not. This reduction in physical contact between ER
and mitochondria could be an underlying cause con-
tributing to the reduction in insulin-stimulated mito-
chondrial Ca2+ uptake and mitochondrial metabolism
seen under certain pathological hypertrophic states.
Insulin signaling is blunted in NE-treated cardiomyocytes
Pathological hypertrophy is associated with a decline in
insulin sensitivity in both animal models and clinical
populations with hypertrophic heart disease [20,21]. To
determine whether canonical insulin signaling was al-
tered in our in vitro cell culture model of NE-induced
hypertrophy, various cellular processes regulated by
insulin were measured. Akt is a serine/threonine kinase
downstream of insulin receptor whose activity is regulated
by phosphorylation [32]. Insulin treatment of control car-
diomyocytes induced phosphorylation of Akt at Ser473
(Figure 4A). This response was reduced in hyper-
trophic cardiomyocytes pre-treated with NE, indicating a
blunting of this early effector of insulin signaling. Consist-
ent with this finding, insulin-stimulated glucose uptake
was also reduced in the NE-treated cardiomyocytes
(Figure 4B).
Previously, we and other groups demonstrated that insu-
lin induces a rise in mitochondrial metabolism, that is fun-
damental to its ability to act as a metabolic regulator
[25,33,34]. Therefore, we evaluated changes in mitochon-
drial respiration 3 h after insulin treatment by measuring
oxygen consumption and mitochondrial membrane poten-
tial. Control cardiomyocytes showed a significant increase
in oxygen consumption in response to insulin stimulation
(134% ±8, p <0.01), whereas insulin did not significantly
increase oxygen consumption in the NE-treated cardio-
myocytes (Figure 4C). In parallel, mitochondrial membrane
potential measured by flow cytometry, showed a very simi-
lar behaviour. Figure 4D shows that insulin increased
mitochondrial membrane potential (138% ±10, p <0.05),whereas pre-treatment with NE completely abolished this
response. Together, these results confirm that the meta-
bolic response to insulin is reduced in NE-treated cardio-
myocytes, consistent with reductions in insulin sensitivity
reported for pathological hypertrophy in vivo. Because
pyruvate dehydrogenase (PDH)-dependent glycolysis can
be up-regulated in hypertrophy, we also analyzed the
expression of five glycolytic genes (glycolytic markers):
hexokinase 2 (Hk2), 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 2 (Pfkfb2), Glut1 (Slc2a1), Glut4 (Slc2a4)
and pyruvate dehydrogenase kinase, isozyme 4 (Pdk4).
Figure 4E shows that expression of Hk2, Pfkfb2, Slc2a1
and Slca2a4 increase additively with insulin and NE treat-
ments. However, in the case of Pdk4, a key enzyme down-
regulated by insulin, NE had the opposite effect, increasing
expression as well as preventing insulin-mediated down-
regulation. These data point to PDK4 regulation of PDH
as a potentially interesting point of regulation between the
glycolytic induction triggered by insulin and the chronic
effects exerted by NE during hypertrophy.
Blocking mitochondrial Ca2+ uptake mimics the
hypertrophic metabolic phenotype
To test for a causative relationship between changes in
mitochondrial Ca2+ uptake and changes in insulin sensitiv-
ity, we pre-treated cardiomyocytes with Ru for 30 min to
inhibit Ca2+ entry into mitochondria [35] and then evalu-
ated the insulin-induced metabolic response of the cells.
The response of Ru-treated cardiomyocytes was a pheno-
typic copy of NE-treated cardiomyocytes (Figure 4).
Insulin-induced Ser473-Akt phosphorylation was reduced
in cardiomyocytes with either Ru-treatment or siRNA-
MCU knockdown (Figure 5A and B). Insulin-induced glu-
cose uptake and stimulation of oxygen consumption were
likewise reduced (Figure 5C-D). Furthermore, the insulin-
induced increase in the oxygen consumption in cardio-
myocytes was also blocked by pre-treatment with the
InsP3R–specific antagonist XeC (which blocks Ca
2+ release
from the ER) as well as by depletion of MCU with
siRNA (Figure 5D). Figure 5E shows the evaluation of
the glycolytic genes assessed previously in Figure 4E.
Consistent with the preceding data, insulin, Ru and
XeC increased expression of the first four markers,
Figure 4 Hypertrophic cardiomyocytes show a reduced insulin response. A) Western blot of p-Akt (Ser473) and Akt (Upper) and densitometric
analysis (lower) of control and hypertrophic NE-treated cardiomyocytes (NE 10 μM, 24 h) either stimulated with insulin 100 nM for 15 min or
left unstimulated. Data were relativized against insulin (white bar) and expressed as mean ± SEM, N= 6, ***P < 0.001 vs. insulin. B) Glucose uptake
of control and hypertrophic NE-treated cardiomyocytes (NE 10 μM for 24 h) either stimulated with insulin 100 nM for 15 min or left unstimulated.
Cytochalasin B (Cyto B) was used as a negative control. Data are expressed as mean ± SEM, N = 7, **P < 0.01, ns: non significant. C) Oxygen
consumption rates of control and hypertrophic cardiomyocytes (NE 10 μM for 24 h) either stimulated with insulin 100 nM for 3 h or left unstimulated.
Data are expressed as mean ± SEM, N = 3, **P < 0.01 vs. control, ns: non significant. D) Mitochondrial membrane potential quantification in control
cardiomyocytes or treated with NE 10 μM for 24 h and stimulated with insulin. CCCP (50 μM, 30 min) was used as a negative control. Data are expressed
as mean± SEM, N= 3, *P < 0.05 vs. control, ns: non significant. E) qPCR for Hk2, Pfkfb2, Slc2a1, Slc2a4 and Pdk4 mRNA levels of control (Ctrl) and hypertrophic
cardiomyocytes (NE 10 μM for 24 h) either stimulated with insulin 100 nM for 3 h or left unstimulated. Data are expressed as mean± SEM, N= 4, *P < 0.05,
**P < 0.01 and ***P < 0.001 vs. Ctrl; ###P < 0.001 vs. Insulin and &&&P < 0.001 vs. NE.
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insulin on Pdk4 expression.
Finally, to better understand the mechanism through
which NE and mitochondrial Ca2+ uptake may be cross
talk with insulin and Akt signalling, we assessed changes
in phosphorylation of IRS-1 at Ser307. Phosphorylation
of this site is inhibitory, uncoupling IRS-1 from the
insulin receptor and decreasing activation of down-
stream targets including Akt [36]. A number of pathwayscan lead to Ser307 phosphorylation including insulin
stimulation itself, thus providing feed back control over
insulin stimulation. Consistent with decrease insulin-
sensitivity in pathological hypertrophy [32] and the
findings in Figure 4A, NE decreased insulin-induced
phosphorylation of IRS-1 (Additional file 5: Figure S5).
In this instance, the effect of Ru and XeC on insulin-
stimulated Ser307 phosphorylation was less pronounced
and not significant, suggesting that the impact of
Figure 5 The blockade of Ca2+ entry to the mitochondria reduces insulin response. A) Western blot of p-Akt (Ser473) and Akt (upper) and
densitometric analysis (lower) of cardiomyocytes treated with ruthenium red (Ru 10 μM for 30 min) either stimulated with insulin (100 nM for 15 min)
or left unstimulated. Data are expressed as mean ± SEM, N = 6, *P < 0.05 vs. insulin. B)Western blot of p-Akt (Ser473) and Akt (upper) and densitometric
analysis (lower) of cardiomyocytes transfected with a siRNA Ctrl or against MCU either stimulated with insulin (100 nM for 15 min) or left unstimulated.
Data are expressed as mean ± SEM, N = 3, *P < 0.05 vs. insulin. C) Glucose uptake of cardiomyocytes treated with ruthenium red (Ru 10 μM for 30 min)
either stimulated with insulin 100 nM for 15 min or left unstimulated. Cytochalasin B (Cyto B) was used as a negative control. Data are expressed as
mean ± SEM, N = 7, **P < 0.01 vs. control, ns: non significant. D) Oxygen consumption rates of cardiomyocytes treated with ruthenium red (Ru 10 μM,
30 min prior stimuli) or xestospongin C (XeC, 100 μM, 30 min prior stimuli) either stimulated with insulin (100 nM for 3 h) or left unstimulated.
Data are expressed as mean ± SEM, N = 3, **P < 0.01 vs. control ns: non significant. E) qPCR for Hk2, Pfkfb2, Slc2a1, Slc2a4 and Pdk4 mRNA levels
of cardiomyocytes treated with ruthenium red (Ru 10 μM for 30 min) or xestospongin C (XeC, 100 mM, 30 min prior stimuli) either stimulated with
insulin (100 nM for 15 min) or left unstimulated. Data are expressed as mean ± SEM, N = 4, *P < 0.05 vs. Ctrl and #P < 0.05 vs. Insulin.
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the direct consequence of changes in insulin receptor sensi-
tivity. This also highlights the complexity of the signalling
mechanisms involved that merit further investigation.
Taken together, these data suggest that Ca2+ entry into
mitochondria is an important aspect of the heart’s
response to insulin, modulating both the activity of
intermediates and the final metabolic effects at the level
of cardiomyocytes. Furthermore, we show that this
pathway of intracellular communication is altered in
pathological, but not physiological hypertrophy and
speculate that changes in this process could underlie the
reduced insulin responses observed in other pathologies.
The possible retrograde modulation of mitochondria to
insulin signaling reveals an important new aspect of
cellular crosstalk, placing mitochondria as an active
participant in intracellular communication (Figure 6).Discussion
In recent decades there have been important advances
in our understanding of the pathways mediating insulin
signaling. The most widely studied is the canonical sig-
naling cascade constituted by PI3K/Akt, that controls
glucose uptake, metabolic activity, and translational re-
sponses to insulin [37]. Ca2+ has also been identified as
an important second messenger acting downstream of
the insulin receptor and shown to be essential in
insulin-mediated glucose uptake in cardiac and skeletal
muscle [38-40]. Our group showed that Ca2+ release
from the ER through the InsP3R is an important compo-
nent of the Ca2+-mediated insulin response in cardio-
myocytes [19]. Mitochondria have a substantial capacity
for Ca2+ storage that is facilitated by their physical and
functional interaction with InsP3Rs in the ER membrane
[41]. As such, poor or excessive mitochondrial Ca2+
Figure 6 Proposed model for insulin-induced mitochondrial Ca2+ uptake in normal and hypertrophic cardiomyocytes. During
hypertrophy there is a decrease in ER-mitochondria physical coupling, disrupting Ca2+ transfers between both organelles, thus leading a diminished
Akt phosphorylation and oxygen consumption in response to insulin.
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http://www.biosignaling.com/content/12/1/68retention represent a potential mechanism contributing
to metabolic imbalance and insulin resistance.
The work presented here is the first to identify mito-
chondrial Ca2+ uptake as a key event in insulin-mediated
signalling pathways in cardiomyocytes. We show that
insulin-induced stimulation of oxidative metabolism via
mitochondrial uptake of Ca2+ released from ER, whereas
it is diminished in norepinephrine-treated cardiomyo-
cytes undergoing pathological hypertrophy (Figure 6).
Our results highlight the involvement of two intracellular
Ca2+ channels: InsP3R, a principal Ca
2+ ER channel, and
MCU, which carries out mitochondrial Ca2+ uptake. The
proximity of these two channels determines the efficiency
of transfer of Ca2+ from ER to mitochondria.
Mitochondrial insulin-dependent Ca2+ signals in
hypertrophic cardiomyocytes
Mobilization of Ca2+ is known to facilitate insulin-
stimulated glucose uptake in diverse cell types [38-40].However, the precise mechanisms of action, the specific
pools of Ca2+ involved, and how these phenomena may
change under pathological conditions are largely unknown.
Here, we evaluated both cytoplasmic and mitochondrial
insulin-dependent Ca2+ signals in cardiomyocytes and
assessed whether signaling is altered in hypertrophy. De-
regulation of cytoplasmic Ca2+ levels and changes in the
expression of various Ca2+ channels are hallmarks of car-
diac hypertrophy [42-44]. However, with regards to cyto-
plasmic Ca2+ signals induced by insulin we found no
alterations in the shape, timing or intensity in hypertrophic
cardiomyocytes. This result, although surprising, does not
preclude the possibility of alterations specific to particular
cellular regions. In contrast, the mitochondrial Ca2+ re-
sponse was blunted specifically in NE-treated cardio-
myocytes, a model of pathological hypertrophy, but not in
cardiomyocytes exposed to IGF-1, as a model of physio-
logical hypertrophy (Figure 2). Mitochondrial Ca2+ uptake
in response to histamine-mediated release of Ca2+ from
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http://www.biosignaling.com/content/12/1/68the ER was likewise reduced in NE-treated cardiomyocytes
compared to control or IGF-1 treated cardiomyocytes.
This result demonstrates that the observed effects are not
particular to insulin, but instead indicate a general de-
crease in the capacity for mitochondrial Ca2+ uptake in
pathological hypertrophy. Our data are consistent with the
work of Fauconnier et al. which described alterations in
cytoplasmic and mitochondrial Ca2+ signaling in response
to electrical stimulation in cardiomyocytes obtained from
obese mice, another pathological condition where the
heart develops insulin resistance [45]. In their study, using
adult cardiomyocytes isolated from wild type and ob/ob
mice, electrically evoked mitochondrial Ca2+ uptake was
increased by insulin in cells from wild type, but not ob/ob.
These findings suggest that, in addition to direct stimula-
tion of mitochondrial Ca2+ uptake, insulin can increase
the magnitude of uptake induced by other stimuli.
Our finding that blocking the entry of Ca2+ to mito-
chondria with Ru decreases insulin-dependent Akt phos-
phorylation suggests that this Ca2+ dynamic is relevant
for proper insulin signaling to Akt. In this context, our
group has previously demonstrated that inhibition of
InsP3R with XeC and the Ca
2+ chelating agent BAPTA-
AM also reduces Akt phosphorylation [19]. Moreover,
we showed that the induction of mitochondrial fragmen-
tation reduces insulin-induced Akt phosphorylation by
reducing mitochondrial Ca2+ uptake [35]. However, fur-
ther investigation will be needed to fully understand the
mechanisms involved in this signalling cross-talk. Taken
together, these findings suggest that a reduction in the
capacity of mitochondria to uptake Ca2+ may be a com-
mon feature of insulin resistance.
ER-mitochondrial coupling in hypertrophic
cardiomyocytes
Although the mechanism and regulatory components in-
volved in mitochondrial Ca2+ uptake after ER release
have been described, alterations in this process in patho-
logical conditions are still unknown. The distance be-
tween ER and mitochondria is a key factor that
determines the efficiency of Ca2+ transfer [46]. The ER
and mitochondrial networks are highly dynamic and can
change their shape and/or distribution in response to
various stimuli. Bravo et al. showed that in early stages of
ER stress, both mitochondria and ER migrate to the peri-
nuclear region of the cell, increasing contacts between both
organelles, enhancing Ca2+ transfer. This ultimately leads
to an increase in mitochondrial metabolism [31]. We
tested whether changes in ER-mitochondria coupling in
pathological hypertrophy could underlie the observed
decrease in insulin-stimulated mitochondrial Ca2+ uptake.
Indeed, Figure 3 shows decreased colocalization and ER-
mitochondrial coupling in pathological (NE) hypertrophied
cardiomyocytes as compared to control or physiological(IGF-1) hypertrophied cardiomyocytes. The increased dis-
tance between the two-organelle populations would
increase the potential for dispersion of Ca2+ released from
the ER and prevent local Ca2+ concentrations at the ER-
mitochondrial interface from reaching the critical concen-
tration required for mitochondrial Ca2+ uptake via the
MCU.
Our data show that reducing mitochondrial Ca2+ uptake
with Ru is sufficient to confer an insulin-resistant pheno-
type with regards to Akt activation, glucose uptake, and
oxygen consumption. Thus, mitochondrial Ca2+ uptake is
not only a downstream target of insulin signaling, it also
appears to participate in feed-forward signaling that helps
to maintain insulin sensitivity.Conclusions
Mitochondrial Ca2+ uptake is a key event in insulin signal-
ling and metabolism in cardiomyocytes. Our findings con-
tribute to a better understanding of the causes that trigger
insulin resistance in pathological hypertrophy. This work
raises important new questions that place mitochondrial
Ca2+ handling at a nodal point of metabolic control and
demonstrate that preservation of this function is essential
for proper cardiac function.Methods
Culture and treatment of cardiomyocytes
Neonatal ventricular cardiomyocytes were prepared from
hearts of 1-3-day-old Sprague Dawley rats as described
previously [47]. They were euthanized by decapitation.
Ventricles were trisected, pooled, and cardiomyocytes
dissociated in a solution of collagenase and pancreatin.
After enzymatic dissociation, cells were selectively
enriched for cardiomyocytes by being pre-plated in
DMEM/M199 (4:1) containing 10% (v/v) foetal bovine
serum, 5% (v/v) foetal calf serum, penicillin, and strepto-
mycin (100 units/ml). Cardiomyocytes were plated at a
density of 2.5x105 or 1.5x106 for microscopy or Western
blot experiments respectively. Serum was withdrawn for
24 h before the cells were treated with insulin (100 nM)
and mitochondrial and cytoplasmic Ca2+ were assessed.
In some experiments, cardiomyocyte hypertrophy was
induced with NE (10 μM) or IGF-1 (100 nM) for 24 h
and then stimulated with insulin. To inhibit the mito-
chondrial Ca2+ uniporter, Ru and siRNA to MCU were
used. The InsP3R, ryanodine receptor and PLC were
inhibited with XeC, ryanodine and U73122, respectively.
Studies were approved by the Institutional Bioethical
Committee, Faculty of Chemical and Pharmaceutical
Sciences, University of Chile, in accordance with the
National Institutes of Health Guide for the Care and
Use of Laboratory Animals published by the US (NIH
Publication, 8th Edition, 2011).
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Small interfering RNAs (siRNAs) for MCU I and II
and negative control (MISSION; Sigma-Aldrich Co.)
were used according to manufacturer’s instructions.
The siRNAs used for knockdown experiments were as
follows: negative control, catalogue number SIC001;
MCU I, sense (5′-CAGAGACCCUGAACGAUGU-3′),
antisense (5′-ACAUCGUUCAGGGUCUCUG-3′); and
MCU II, sense (5′-GGCUUACCUGGUGGGAAUA-3′),
antisense (5′-UAUUCCCACCAGGUAAGCC-3’). Both
siRNAs were tested, obtaining the best results with the
siRNA that we called II, which was the one used for all the
subsequent experiments (Additional file 2: Figure S2).
Intracellular and mitochondrial Ca2+ determinations
Cytosolic Ca2+ levels were determined in cardiomyocytes
preloaded with Fluo3-AM (5.4 μM, 30 min) or Fura2
(5 μM, 30 min), as described previously [19,48]. To deter-
mine mitochondrial Ca2+ levels, images were obtained from
cultured cardiomyocytes preloaded with Rhod-FF (5.4 μM,
30 min) [49,50]. At the end of each measurement, CCCP
10 μM was used as control. Both determinations were per-
formed in an inverted confocal microscope (Carl Zeiss
LSM-5, Pascal 5 Axiovert 200 microscope).
ER and mitochondrial network imaging
For ER and mitochondrial imaging, cells were treated
during 30 min with 200 nM ER-Tracker red and with
400 nM MitoTracker Green, respectively. Confocal
image stacks were captured with an inverted confocal
microscope (Carl Zeiss LSM-5, Pascal 5 Axiovert 200
microscope).
Image processing
For mitochondrial network and ER colocalization, one
focal plane was analyzed. The images obtained were
deconvolved using the ImageJ software. Colocalization
between organelles was quantified using the Manders’ al-
gorithm, as previously described [24,30,31,51]. For each
independent experiment, 10–15 cells were registered.
Mitochondrial dynamics analysis
Cells were incubated for 30 min with MitoTracker
Green FM (400 nM) with or without Rhod-FF (5.4 μM)
and maintained in Krebs solution. Confocal image stacks
were captured with a Leica TCS SP5 confocal micro-
scope and a Plan-APOCHROMAT 63x/1.4 Oil DIC ob-
jective as previously described [24,25]. Images were
deconvolved with ImageJ software (National Institutes of
Health), and volume reconstitution of Z-stacks of thre-
sholded images was performed. The number and indi-
vidual volume of each object (mitochondria) were
quantified with the ImageJ 3D Object Counter plug-in.Each experiment was done at least three times, and
16–25 cells per condition were quantified.
Western blot
The primary antibodies used were anti-β-MHC (1:1000,
Sigma-Aldrich), anti-phospho-Akt (Ser473) (1:1000, Cell
Signaling), anti-Akt (1:1000, Cell Signaling), anti IRS-1
(1:1000, Cell Signaling), anti-phospho-IRS-1 (Ser307)
(1:500, Cell Signaling) and anti-MCU (1:2000, Abcam).
Then the blots were incubated with a horseradish
peroxidase-coupled secondary antibody (1:5000, Pierce).
ImageJ software was used for image densitometry.
Oxygen consumption
Cardiomyocytes were plated and treated according each ex-
periment. Cells were then trypsinized, and the suspension
was placed in a chamber at 25°C, coupled to a Clark elec-
trode 5331 (Yellow Springs Instruments) where the oxygen
consumption was measured polarographically [31,50].
Glucose uptake
Cardiomyocytes were rinsed twice with HEPES-buffered
saline. Inhibitors were added for 30 min and insulin dur-
ing the last 10 min. Glucose uptake was measured using
10 mM [3H]2-deoxyglucose [19].
Flow cytometry analysis of mitochondrial membrane
potential
ΔΨm was measured after loading cardiomyocytes with
TMRM (200 nM) for 30 min. Afterward, cells underwent
trypsinization, and fluorescence was assessed by flow cy-
tometry (excitation/emission 543/560) with a FACScan
system (Becton Dickinson). CCCP (50 mM) and oligo-
mycin (10 mM) for 30 min were used as positive and
negative controls for the ΔΨm measurements.
qPCR
Real-time PCR was performed with SYBR green (Ap-
plied Biosystems) as previously described [25]. Data for
each transcript was normalized to 18S rRNA as internal
control with the 2-ΔΔCt method. Primers used were as
follows: MCU rat forward 5′-GCGCCAGGAATATGTT
TATC-3′; MCU rat reverse 5′-TTGCATCCTTGAGTT
GATTG-3′; Hk2 rat forward 5′-CGAATCAAAGAGAA
CAAGGG-3′; Hk2 rat reverse 5′-CAAAATGGGGAT
GTTTCTTG-3′; Pfkfb2 rat forward 5′-CTGGAGG
TAAAAGTGTCAAG-3′; Pfkfb2 rat reverse 5′-ACGA
GAGGTCCTTATCATAG-3′; Slc2a1 rat forward 5′-CA
ATATGTGGAGCAACTGTG-3′; Slc2a1 rat reverse 5′-
AGTAGGTGAAGATGAAGAAGAG-3′; Slc2a4 rat for-
ward 5′-AAGTGATTGAACAGAGCTAC-3′; Slc2a4 rat
reverse 5′-CTTTTCCTTCCCAACCATTG-3′; Pdk4 rat
forward 5′-AATCAAGATTTCTGACCGAG-3′; Pdk4 rat
reverse 5′-CTGACATGGAATAGAGATTCAG-3′.
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Data are presented either as means ± SEM of a number
(n) of independent experiments or as examples of repre-
sentative experiments performed on at least three separ-
ate occasions. Data were analysed by analysis of variance
and comparisons between groups were performed using
a protected Tukey t test. A value of P < 0.05 was chosen
as the limit of statistical significance.
Additional files
Additional file 1: Figure S1. Measurement of Rhod-FF fluorescence for
Ca2+ signalling in cardiomyocytes. A) Representative confocal images
stained with MitoTracker green (green, top left) and Rhod-FF (red, top
right). The merge between MitoTracker green and Rhod-FF is shown in
the down left corner and the intensity correlation analysis and the
Pearson coefficient is shown in the down right corner. Scale bar: 10 μm.
B) Representative measurement of Rhod-FF fluorescence representing
the insulin-induced mitochondrial Ca2+ signal. Insulin (100 nM) was
added at 100 s, and CCCP (50 μM) was added at 350 s. C) Representative
confocal images of cells loaded with MitoTracker Green (400 nM for
30 min) alone, or MitoTracker Green (400 nM for 30 min) and Rhod-FF
(5.4 μM for 30 min). Scale bar represents 10 μm. D) Number of
mitochondria per cell and individual mitochondrial volume were
determined for the cells in C). Data are expressed as mean ± SEM (n = 3).
Additional file 2: Figure S2. Ruthenium Red (Ru) and MCU siRNA
knockdown controls. A) Representative measures of Fura2 fluorescence-
associated CCCP (50 μM) or thapsigargin (Thapsi, 500 μM) -induced cytosolic
Ca2+ signals in cardiomyocytes pre-treated with (red line) or without (Ctrl,
black line) Ruthenium Red (Ru, 10 μM) for 3 h. B) Basal Fura2 Fluorescence
previous to CCCP or Thapsi stimuli. C) Initial Ca2+-related fluorescence rate
(slope) of control and Ru (10 μM) pre-treated cardiomyocytes after CCCP
(50 μM) or Thapsi (500 μM) stimulation at 150 s. The results are representative
of 4 independent experiments (N = 4), where 10–20 cells were analysed.
Data are expressed as mean ± SEM. D) qPCR for MCU mRNA levels of
cardiomyocytes transfected with control, MCU (I) or MCU (II) siRNA.
E) Western blot of MCU and β-tubulin (upper) and densitometric analysis
(lower) of cardiomyocytes transfected with control, MCU (I) or MCU (II) siRNA.
Data are expressed as mean ± SEM, N = 3, *P < 0.05, **P < 0.01 and
***P < 0.001 vs. siRNA Control (Ctrl).
Additional file 3: Figure S3 Cardiomyocyte hypertrophy induced by
NE. A) Representative images of cultured neonatal rat cardiomyocytes
treated with or without (Control) NE 10 μM for the indicated times. Cells
were fixed and stained with phalloidin-rhodamine (orange) for sarcomere
detection and with Höescht (blue) for nuclei detection. Lower panels
show the fluorescence intensity profiles of the lines depicted in the
respective images. Scale bar: 20 μm. B) Cell area, C) perimeter and D)
percentage of sarcomeric cardiomyocytes were calculated measuring at
least 100 cells per condition. E) Western blot of β-MHC and β-actin
(upper) and densitometric analysis (lower) of cardiomyocytes treated with
or without NE 10 μM for the indicated times. Data are expressed as
mean ± SEM, N = 3, *P < 0.05, **P < 0.01 and ***P < 0.001 vs Control.
Additional file 4: Figure S4. ER Ca2+ content in hypertrophic
cardiomyocytes. A) Cytoplasmic Ca+2 signals induced by thapsigargin 500 μM
in control and NE 10 μM or IGF-1 100 nM treated cardiomyocytes. Caffeine
5 mM was added as a negative control. B) Area under the curve of
cytoplasmic Ca2+ signals of control and NE and IGF-1 treated cardiomyocytes
after thapsigargin 500 μM stimulation between 100 and 300 s. Data are
expressed as mean ± SEM, N = 3, **P < 0.01 vs Control.
Additional file 5: Figure S5. IRS-1 phosphorylation in hypertrophic
cardiomyocytes. A) Western blot of p-IRS-1 (Ser307) and IRS-1 (left) and
densitometric analysis (right) of control and hypertrophic NE treated
cardiomyocytes (NE 10 μM, 24 h) either stimulated with insulin 100 nM
for 15 min or left unstimulated. Data were relativized against insulin
(white bar) and expressed as mean ± SEM, N = 4, ***P < 0.001 vs. insulin.
B) Western blot of p-IRS-1 (Ser307) and IRS-1 of control, Ruthenium Red(Ru, 10 μM, 30 min prior stimuli) and xestospongin C (XeC, 100 μM,
30 min prior stimuli) treated cardiomyocytes either stimulated with
insulin 100 nM for 15 min or left unstimulated. Data were relativized
against insulin (white bar) and expressed as mean ± SEM, N = 3,
*P < 0.001 vs. Insulin.
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